SE9704870D0 - New pharmaceutical formulation I - Google Patents

New pharmaceutical formulation I

Info

Publication number
SE9704870D0
SE9704870D0 SE9704870A SE9704870A SE9704870D0 SE 9704870 D0 SE9704870 D0 SE 9704870D0 SE 9704870 A SE9704870 A SE 9704870A SE 9704870 A SE9704870 A SE 9704870A SE 9704870 D0 SE9704870 D0 SE 9704870D0
Authority
SE
Sweden
Prior art keywords
dosage form
atpase inhibitor
pharmaceutical formulation
new pharmaceutical
released
Prior art date
Application number
SE9704870A
Other languages
English (en)
Swedish (sv)
Inventor
Per Johan Lundberg
Brita Sjoeblom
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9704870A priority Critical patent/SE9704870D0/xx
Publication of SE9704870D0 publication Critical patent/SE9704870D0/xx
Priority to ZA9811234A priority patent/ZA9811234B/xx
Priority to ARP980106245A priority patent/AR017202A1/es
Priority to TW087120441A priority patent/TWI240637B/zh
Priority to MA25384A priority patent/MA26577A1/fr
Priority to TNTNSN98230A priority patent/TNSN98230A1/fr
Priority to DZ980296A priority patent/DZ2686A1/xx
Priority to HU0200618A priority patent/HUP0200618A3/hu
Priority to UA2000063359A priority patent/UA69396C2/uk
Priority to YU36600A priority patent/YU36600A/sh
Priority to SK808-2000A priority patent/SK284545B6/sk
Priority to CZ20002313A priority patent/CZ299227B6/cs
Priority to NZ505135A priority patent/NZ505135A/en
Priority to IL13682398A priority patent/IL136823A/xx
Priority to JP2000525085A priority patent/JP4907765B2/ja
Priority to PCT/SE1998/002369 priority patent/WO1999032093A1/en
Priority to CNB988137402A priority patent/CN1245155C/zh
Priority to EEP200000395A priority patent/EE04417B1/xx
Priority to CA002315927A priority patent/CA2315927C/en
Priority to SI9830589T priority patent/SI1043977T1/xx
Priority to IDW20001201A priority patent/ID27040A/id
Priority to PL98341565A priority patent/PL341565A1/xx
Priority to DK98964632T priority patent/DK1043977T3/da
Priority to AT98964632T priority patent/ATE252379T1/de
Priority to US09/555,720 priority patent/US6610323B1/en
Priority to EP98964632A priority patent/EP1043977B1/en
Priority to PT98964632T priority patent/PT1043977E/pt
Priority to TR2000/01982T priority patent/TR200001982T2/xx
Priority to KR1020007006907A priority patent/KR100616027B1/ko
Priority to ES98964632T priority patent/ES2209240T3/es
Priority to DE69819205T priority patent/DE69819205T2/de
Priority to RU2000116012/14A priority patent/RU2205028C2/ru
Priority to AU19913/99A priority patent/AU759311B2/en
Priority to BR9814389-1A priority patent/BR9814389A/pt
Priority to MYPI98005795A priority patent/MY130765A/en
Priority to EG158698A priority patent/EG23875A/xx
Priority to HR20000381 priority patent/HRP20000381B1/xx
Priority to IS5541A priority patent/IS2184B/is
Priority to NO20003219A priority patent/NO20003219L/no
Priority to BG104619A priority patent/BG65008B1/bg
Priority to HK01105215A priority patent/HK1034668A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE9704870A 1997-12-22 1997-12-22 New pharmaceutical formulation I SE9704870D0 (sv)

Priority Applications (41)

Application Number Priority Date Filing Date Title
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I
ZA9811234A ZA9811234B (en) 1997-12-22 1998-12-08 Oral pharmaceutical pulsed release dosage form
ARP980106245A AR017202A1 (es) 1997-12-22 1998-12-09 Forma de dosificacion farmaceutica oral de liberacion pulsada y procedimiento para la preparacion de la misma y su uso para la manufactura de unmedicamento
TW087120441A TWI240637B (en) 1997-12-22 1998-12-09 Oral pharmaceutical pulsed release dosage form
MA25384A MA26577A1 (fr) 1997-12-22 1998-12-11 Formulation pharmaceutique orale a liberation pulsee
TNTNSN98230A TNSN98230A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale a liberation pulsee
DZ980296A DZ2686A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale à libération pulsée.
BR9814389-1A BR9814389A (pt) 1997-12-22 1998-12-17 Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
CA002315927A CA2315927C (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
US09/555,720 US6610323B1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
YU36600A YU36600A (sh) 1997-12-22 1998-12-17 Oralni farmaceutski oblik za doziranje sa pulsnim oslobađanjem
SK808-2000A SK284545B6 (sk) 1997-12-22 1998-12-17 Orálna farmaceutická dávková forma s pulzačným uvoľňovaním
CZ20002313A CZ299227B6 (cs) 1997-12-22 1998-12-17 Enterálne potažená farmaceutická dávková forma, zpusob prípravy a použití této dávkové formy, jakoži vrstvená tableta nebo peleta pro dávkovou formu
NZ505135A NZ505135A (en) 1997-12-22 1998-12-17 Composition comprising a proton pump inhibitor (H+,K+-ATPase inhibitor) which provides two or more discrete release pulses in the small and/or large intestines
IL13682398A IL136823A (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
JP2000525085A JP4907765B2 (ja) 1997-12-22 1998-12-17 経口医薬パルス放出剤形
PCT/SE1998/002369 WO1999032093A1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
CNB988137402A CN1245155C (zh) 1997-12-22 1998-12-17 口服药用脉冲释放剂型
EEP200000395A EE04417B1 (et) 1997-12-22 1998-12-17 Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
HU0200618A HUP0200618A3 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form and process for its preparation
SI9830589T SI1043977T1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
IDW20001201A ID27040A (id) 1997-12-22 1998-12-17 Bentuk sediaan dengan pelepasan berpulsa dari bahan farmasi oral
PL98341565A PL341565A1 (en) 1997-12-22 1998-12-17 Oral dosage form featured by pulse-type release of active substance
DK98964632T DK1043977T3 (da) 1997-12-22 1998-12-17 Oral farmaceutisk doseringsform baseret på pulserende frigørelse
AT98964632T ATE252379T1 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform beruhend auf stossweiser freisetzung
UA2000063359A UA69396C2 (uk) 1997-12-22 1998-12-17 ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА З ДИСКРЕТНИМ ВИВІЛЬНЕННЯМ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ (ВАРІАНТИ) ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І СПОСІБ ЛІКУВАННЯ (ВАРІАНТИ)
EP98964632A EP1043977B1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
PT98964632T PT1043977E (pt) 1997-12-22 1998-12-17 Forma de dosagem farmaceutica oral de libertacao por impulsos
TR2000/01982T TR200001982T2 (tr) 1997-12-22 1998-12-17 Farmasötik vurulu salınımlı oral dozaj şekli.
KR1020007006907A KR100616027B1 (ko) 1997-12-22 1998-12-17 경구용 제약학적 펄스 방출형 투여 제형
ES98964632T ES2209240T3 (es) 1997-12-22 1998-12-17 Formas de dosificacion farmaceutica oral de liberacion por pulsos.
DE69819205T DE69819205T2 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform beruhend auf stossweiser freisetzung
RU2000116012/14A RU2205028C2 (ru) 1997-12-22 1998-12-17 Пероральная фармацевтическая лекарственная форма с дискретным высвобождением
AU19913/99A AU759311B2 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
EG158698A EG23875A (en) 1997-12-22 1998-12-21 Oral pharmaceutical pulsed release dosage form
MYPI98005795A MY130765A (en) 1997-12-22 1998-12-21 Oral pharmaceutical pulsed release dosage form
HR20000381 HRP20000381B1 (en) 1997-12-22 2000-06-08 Stable complexes of poorly soluble compounds
IS5541A IS2184B (is) 1997-12-22 2000-06-19 Lyfjaform með áfangalosun til inntöku um munn
NO20003219A NO20003219L (no) 1997-12-22 2000-06-21 Oral farmasøytisk doseringsform med pulsert frigivningsvirkning
BG104619A BG65008B1 (bg) 1997-12-22 2000-07-17 Орална лекарствена дозирана форма с импулсно освобождаване
HK01105215A HK1034668A1 (en) 1997-12-22 2001-07-26 Oral pharmaceutical pulsed release dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I

Publications (1)

Publication Number Publication Date
SE9704870D0 true SE9704870D0 (sv) 1997-12-22

Family

ID=20409572

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I

Country Status (40)

Country Link
US (1) US6610323B1 (ja)
EP (1) EP1043977B1 (ja)
JP (1) JP4907765B2 (ja)
KR (1) KR100616027B1 (ja)
CN (1) CN1245155C (ja)
AR (1) AR017202A1 (ja)
AT (1) ATE252379T1 (ja)
AU (1) AU759311B2 (ja)
BG (1) BG65008B1 (ja)
BR (1) BR9814389A (ja)
CA (1) CA2315927C (ja)
CZ (1) CZ299227B6 (ja)
DE (1) DE69819205T2 (ja)
DK (1) DK1043977T3 (ja)
DZ (1) DZ2686A1 (ja)
EE (1) EE04417B1 (ja)
EG (1) EG23875A (ja)
ES (1) ES2209240T3 (ja)
HK (1) HK1034668A1 (ja)
HR (1) HRP20000381B1 (ja)
HU (1) HUP0200618A3 (ja)
ID (1) ID27040A (ja)
IL (1) IL136823A (ja)
IS (1) IS2184B (ja)
MA (1) MA26577A1 (ja)
MY (1) MY130765A (ja)
NO (1) NO20003219L (ja)
NZ (1) NZ505135A (ja)
PL (1) PL341565A1 (ja)
PT (1) PT1043977E (ja)
RU (1) RU2205028C2 (ja)
SE (1) SE9704870D0 (ja)
SK (1) SK284545B6 (ja)
TN (1) TNSN98230A1 (ja)
TR (1) TR200001982T2 (ja)
TW (1) TWI240637B (ja)
UA (1) UA69396C2 (ja)
WO (1) WO1999032093A1 (ja)
YU (1) YU36600A (ja)
ZA (1) ZA9811234B (ja)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
JP4988088B2 (ja) 1998-08-12 2012-08-01 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾール、もしくはピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾールの骨格を有する化合物、またはその薬学的に許容される塩の経口投与形組成物を固定的に組み合わせた組成物
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1552833B1 (en) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
MXPA05004422A (es) * 2002-10-25 2007-11-22 Collegium Pharmaceutical Inc Composiciones de milnacipran de liberacion pulsatil.
US20070036851A1 (en) * 2002-12-23 2007-02-15 Deepak Thassu Acid labile drug compositions
JP2004231520A (ja) * 2003-01-28 2004-08-19 Nichiko Pharmaceutical Co Ltd 保存安定性及び溶出速度に優れた医薬組成物
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
WO2004082665A1 (ja) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
MXPA06002316A (es) * 2003-09-03 2006-05-19 Boehringer Ingelheim Int Capsula que contiene granulos de sustancia activa con diferentes perfiles de liberacion.
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
JP5563731B2 (ja) * 2003-09-26 2014-07-30 アルザ・コーポレーシヨン オピオイドおよび非オピオイド鎮痛薬の制御放出製剤
JP4919801B2 (ja) 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
CN1938026A (zh) * 2004-03-26 2007-03-28 卫材R&D管理有限公司 控释制剂及其制造方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) * 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
AU2011205024B2 (en) * 2004-06-16 2012-09-06 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
US7226454B2 (en) * 2004-12-07 2007-06-05 Arizant Healthcare Inc. Warming device with varied permeability
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
EP1754471A1 (de) * 2005-08-18 2007-02-21 ORAMON-Arzneimittel GmbH & Co. KG Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
JPWO2007037259A1 (ja) * 2005-09-29 2009-04-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 生体内での崩壊性を向上させたパルス製剤
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US20090104264A1 (en) * 2005-12-28 2009-04-23 Takeda Pharmaceutical Company Limited Controlled release solid preparation
SG184754A1 (en) 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
KR101784001B1 (ko) 2006-04-04 2017-10-23 케이지 액퀴지션 엘엘씨 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
DK2046334T3 (da) 2006-07-25 2014-08-25 Vecta Ltd Sammensætninger og fremgangsmåder til at hæmme mavesyresekretion ved at anvende derivater af små dicarboxylsyrer i kombination med PPI
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
GB2461822B (en) * 2007-03-20 2011-09-21 Isp Investments Inc Meltable binder for melt granulation and/or pelletization
CA2694602A1 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
US8173158B2 (en) * 2007-10-12 2012-05-08 Takeda Pharmaceuticals U.S.A., Inc. Methods of treating gastrointestinal disorders independent of the intake of food
US20110020439A1 (en) * 2008-03-24 2011-01-27 Shrenik Annasaheb Kole Delayed release compositions of duloxetine
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US10029089B2 (en) 2010-10-15 2018-07-24 Research Foundation For The State University Of New York, The Compositions and methods for enhancing the biological response to chemical agents and physical stimuli
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017146052A1 (ja) * 2016-02-23 2017-08-31 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
CN105796531A (zh) * 2016-04-13 2016-07-27 中国药科大学 一种右旋兰索拉唑择时脉冲控释微丸制剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6915258B2 (ja) * 2016-10-21 2021-08-04 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
EP0384646B1 (en) 1989-02-16 1993-06-09 Btg International Limited Dispensing device
GB8903564D0 (en) 1989-02-16 1989-04-05 Rashid Abdul Drug dispensing device
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
JPH04273816A (ja) * 1991-02-26 1992-09-30 Tanabe Seiyaku Co Ltd パルス放出型有核錠
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
MX9700152A (es) * 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
JP3350054B2 (ja) 1994-07-08 2002-11-25 アストラゼネカ・アクチエボラーグ 複数単位の錠剤化された剤形▲ｉ▼
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals

Also Published As

Publication number Publication date
JP2001526213A (ja) 2001-12-18
NZ505135A (en) 2002-06-28
CN1245155C (zh) 2006-03-15
MA26577A1 (fr) 2004-12-20
AU1991399A (en) 1999-07-12
BG104619A (en) 2001-04-30
CN1284868A (zh) 2001-02-21
CZ299227B6 (cs) 2008-05-21
UA69396C2 (uk) 2004-09-15
EG23875A (en) 2007-11-27
CA2315927C (en) 2008-03-18
TNSN98230A1 (fr) 2005-03-15
NO20003219L (no) 2000-08-22
EP1043977A1 (en) 2000-10-18
DK1043977T3 (da) 2004-02-09
KR100616027B1 (ko) 2006-08-28
CZ20002313A3 (cs) 2000-11-15
BR9814389A (pt) 2000-10-10
ATE252379T1 (de) 2003-11-15
AU759311B2 (en) 2003-04-10
EP1043977B1 (en) 2003-10-22
TWI240637B (en) 2005-10-01
CA2315927A1 (en) 1999-07-01
KR20010033427A (ko) 2001-04-25
PT1043977E (pt) 2004-03-31
MY130765A (en) 2007-07-31
ZA9811234B (en) 1999-06-22
SK8082000A3 (en) 2001-02-12
ID27040A (id) 2001-02-22
IS2184B (is) 2006-12-15
SK284545B6 (sk) 2005-06-02
NO20003219D0 (no) 2000-06-21
JP4907765B2 (ja) 2012-04-04
DE69819205T2 (de) 2004-08-26
DE69819205D1 (de) 2003-11-27
EE04417B1 (et) 2005-02-15
WO1999032093A1 (en) 1999-07-01
DZ2686A1 (fr) 2003-03-29
BG65008B1 (bg) 2006-12-29
US6610323B1 (en) 2003-08-26
PL341565A1 (en) 2001-04-23
HUP0200618A2 (hu) 2002-07-29
YU36600A (sh) 2003-01-31
IL136823A (en) 2005-08-31
TR200001982T2 (tr) 2001-02-21
HRP20000381A2 (en) 2000-12-31
ES2209240T3 (es) 2004-06-16
HUP0200618A3 (en) 2003-04-28
IL136823A0 (en) 2001-06-14
HK1034668A1 (en) 2001-11-02
EE200000395A (et) 2002-02-15
IS5541A (is) 2000-06-19
HRP20000381B1 (en) 2004-12-31
RU2205028C2 (ru) 2003-05-27
AR017202A1 (es) 2001-08-22

Similar Documents

Publication Publication Date Title
SE9704870D0 (sv) New pharmaceutical formulation I
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
NO934284D0 (no) Farmas!ytisk preparat inneholdende et definert lipidsystem
DE69725860D1 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
HRP20020158B1 (en) Action of synergistic combination
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
ES2194003T3 (es) Huperzina a racemica.
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
PT880520E (pt) Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase
CA2225628A1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
SI0841904T1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
ES2082524T3 (es) Medicamento de liberacion retardada que contiene un derivado de dihidropiridina en forma de nanosol y su preparacion.